Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

Be Biopharma (‘Be Bio’), a leader in the development of B cells as medicines, founded by the Longwood Fund, David Rawlings, MD, and Richard James, PhD, today announced $52 million in Series A funding led by Atlas Venture and RA Capital Management and joined by Alta Partners, Longwood Fund and Takeda Ventures, Inc. The company plans to use this funding to specifically engineer B cells to treat a range of diseases, building on the pioneering work of Drs. Rawlings and James at the Seattle Children’s Research Institute; B cells are prolific protein producers that can be collected from peripheral blood, have a programmable lifetime that could last decades, can target specific tissues, and have a wide, customizable functionality.

Be Biopharma is a leader in the development of B cells as medicines to treat human body disease in native protein factories. Precisely engineering B cells to use their inherent drug-like properties – remarkable protein production, selective tissue targeting, and fine-tuning of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, re-dosable and administered without toxic conditioning, creating new avenues for stopping or reversing serious diseases such as cancer, autoimmune conditions and enzyme deficiency. Founded by the Longwood Fund and B Cell Engineering pioneers David Rawlings, MD, and Richard James, PhD, Be Biopharma is re-imagining medicine based on the power of B cell therapy (bebiopharma) (com)

Please note that this piece of work originally appeared in English at As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at

Leave a Reply

Your email address will not be published. Required fields are marked *